米达唑格 | 80614-27-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 米达唑格
• 中文别名: 咪唑格雷
• 英文名称: Midazogrel
• 英文别名: 1-[(E)-3-phenylmethoxyoct-1-enyl]imidazole
• CAS: 80614-27-3
• 化学式: C₁₈H₂₄N₂O
• 分子量: 284.4
• InChiKey: YPIURPNVKACZQH-ACCUITESSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• A method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptor antagonist
  申请人：CIBA-GEIGY AG

  公开号：EP0449764A2

  公开（公告）日：1991-10-02

  A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more uricosurics are also set forth and included within this invention.

  本发明公开了一种降低有需要的哺乳动物的血清尿酸和/或增加其肾脏对尿酸的清除率的方法，该方法包括向哺乳动物施用尿酸有效量的血栓素合成酶抑制剂、血栓素受体拮抗剂或两者的组合尿酸有效量。具有一种或多种上述物质与一种或多种尿素合剂的组合物也被提出并包括在本发明中。
• MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP0665023A1

  公开（公告）日：1995-08-02

  A medical material comprising a polymer or copolymer of a polar vinyl derivative and containing an antithrombocytic agent. Since it can release the antithrombocytic agent in an effective concentration for long, it has a high anticoagulant effect and the effect of preventing platelet loss by activating the same.

  一种医用材料，由极性乙烯基衍生物的聚合物或共聚物组成，并含有抗血栓形成剂。由于它能长期释放有效浓度的抗血栓形成剂，因此具有很高的抗凝血效果，并能通过激活血小板防止其流失。
• METHOD OF INHIBITING BLOOD COAGULATION DURING EXTRACORPOREAL BLOOD CIRCULATION AND DEVICE FOR RELEASING ANTITHROMBOTIC DRUG USED THEREIN
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP0704223A1

  公开（公告）日：1996-04-03

  A method of inhibiting the coagulation of blood during the extracorporeal circulation thereof by bringing a member for releasing an antithrombotic drug, prepared by dispersing a difficulty water-soluble antithrombotic drug in a macromolecular material, into contact with the circulating blood. A device for releasing an antithrombotic drug to be used in the above method comprises either the drug releasing member contained in a vessel provided with blood inlet and outlet ports at the respective ends thereof or the drug releasing member constituting at least the inner wall surface of the vessel. As the antithrombotic agent can be released sustainedly from the drug releasing member, the blood coagulation in the blood circuit can be inhibited as a result of the contact of the blood with the member during the extracorporeal circulation.

  一种在体外循环过程中抑制血液凝固的方法，其方法是将通过在高分子材料中分散难溶于水的抗血栓药物而制备的释放抗血栓药物的部件与循环血液接触。在上述方法中使用的抗血栓药物释放装置包括：药物释放部件装在一个容器中，容器的两端分别设有血液入口和出口；或者药物释放部件至少构成容器的内壁表面。由于抗血栓药物可从药物释放部件中持续释放，在体外循环过程中，血液与该部件的接触可抑制血路中的血液凝固。